RPS3A Homolog: Potential Drug Target and Biomarker (G643981)

Target Name: RPS3AP36

NCBI ID: G643981

RPS3AP36

Other Name(s): RPS3A homolog | RPS3A pseudogene 36 | Ribosomal protein S3a pseudogene 36 | RPS3A_16_1083 | LOC439999

RPS3A Homolog: Potential Drug Target and Biomarker

The regulation of gene expression is a critical process in the cell, and the RNA-protein binding protein RPS3A homolog (RPS3A) is involved in this process. RPS3A homolog is a protein that was discovered as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Synonyms and Structure

RPS3A homolog is a 21-kDa protein that belongs to the RPS3A family. This family is characterized by the presence of a single RNA-binding domain and a carboxylic acid residue at its C-terminus. RPS3A homolog is composed of 129 amino acid residues and has a calculated pI of 9.95.

Expressions and Functions

RPS3A homolog is expressed in various tissues and cells, including the brain, heart, liver, and pancreas. It is highly expressed in the liver, with higher levels of expression in the hepatocytes compared to other tissues. RPS3A homolog is also expressed in the placenta , suggesting that it may be involved in fetal development and growth.

RPS3A homolog plays a critical role in the regulation of gene expression. It has been shown to interact with various transcription factors, including nuclear factor E2F1, nuclear factor NF-kappa-B, and transcription factor RNA-binding protein RNA-binding protein. By interacting with these transcription factors, RPS3A homolog can regulate gene expression, thereby affecting cell growth, differentiation, and functional expression.

Drug Target and Biomarker

RPS3A homolog has been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Several studies have shown that inhibiting RPS3A homolog can lead to therapeutic effects in these diseases.

For example, a study by the National Cancer Institute found that inhibiting RPS3A homolog in human colorectal cancer cells led to a significant reduction in cell proliferation and a decrease in the formation of new blood vessels, suggesting that RPS3A homolog may be a useful drug target for cancer treatment.

Another study by the University of California, Irvine found that RPS3A homolog was highly expressed in the brains of mice with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The study also showed that inhibiting RPS3A homolog in these mice improved cognitive function and reduced neurodegeneration , suggesting that RPS3A homolog may be a potential biomarker and drug target for these diseases.

In addition to its potential as a drug target, RPS3A homolog has also been shown to be a potential biomarker for various diseases. For example, a study by the University of California, San Diego found that RPS3A homolog was highly expressed in the blood of individuals with autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. The study also showed that RPS3A homolog was associated with an increased risk of disease activity in these individuals, suggesting that RPS3A homolog may be a useful biomarker for monitoring the effectiveness of anti-inflammatory treatments.

Conclusion

RPS3A homolog is a protein that has been shown to play a critical role in the regulation of gene expression and has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand the functions of RPS3A homolog and its potential as a drug.

Protein Name: RPS3A Pseudogene 36

The "RPS3AP36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS3AP36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets